Colossal Biosciences

“Colossal Biosciences is seeking to raise at a valuation of $20–30 billion, doubling from its January 2025 valuation of $10.2 billion in roughly 18 months.”

“The company has spun off two businesses, plastic degradation company Breaking and DNA analytics software company Form Bio.”

“Investors believe its work could be foundational in pharmaceuticals, climate change reversal, and longevity.”

“CEO Ben Lamm told Rolling Stone in May that he expects to create an artificial womb for mammals within a year, opening the door to human usage.”